Meet the unmet medical needs using Myoblast Transfer Therapy
The Company
MyoMed Bio is a biotechnology company revolutionizing the field of regenerative medicine. Our proprietary Myoblast Transfer Therapy (MTT) encapsulates immense potential for the treatment of heart failure, Duchenne Muscular Dystrophy (DMD) and other muscle related diseases.
The Founder
The Founder is Peter K. Law who invented the MTT which involves transfer of myoblasts (muscle progenitor cells) into patients. Our team has extensive experience in clinical studies
and product development.
Mission & Values
We are committed to advancing the MTT technology to the fullest extent.